<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ecna</journal-id><journal-title-group><journal-title xml:lang="ru">Экономика науки</journal-title><trans-title-group xml:lang="en"><trans-title>Economics of Science</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2410-132X</issn><issn pub-type="epub">2949-4680</issn><publisher><publisher-name>Delo Publishing house</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">ecna-67</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Тренды развития глобальной науки</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Trends in the development of the global science</subject></subj-group></article-categories><title-group><article-title>ЭВОЛЮЦИЯ МЕХАНИЗМОВ ТРАНСНАЦИОНАЛИЗАЦИИ ИССЛЕДОВАНИЙ И РАЗРАБОТОК ДЛЯ СОКРАЩЕНИЯ ИХ ЖИЗНЕННОГО ЦИКЛА</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of mechanisms for trans-nationalizing research and development for reducing life cycle</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>КУРАКОВ</surname><given-names>Ф. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurakov</surname><given-names>F. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>старший научный сотрудник</p></bio><email xlink:type="simple">kurakov-fa@ranepa.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Центра научно-технической экспертизы ИПЭИ РАНХиГС при Президенте РФ, г. Москва, Россия<country>Россия</country></aff><aff xml:lang="en">The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>09</day><month>11</month><year>2016</year></pub-date><volume>2</volume><issue>3</issue><fpage>224</fpage><lpage>230</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; КУРАКОВ Ф.А., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">КУРАКОВ Ф.А.</copyright-holder><copyright-holder xml:lang="en">Kurakov F.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ecna.elpub.ru/jour/article/view/67">https://ecna.elpub.ru/jour/article/view/67</self-uri><abstract><p>Показано, что одновременно с транснационализацией наукоемких и высокотехнологичных производств нарастают явления транционализации научно-технологической сферы и глобального венчурного капитала. Оценены масштабы диффузии российского венчурного капитала и его инвестиционные предпочтения. На примере проектов, связанных с разработкой нового поколения противоопухолевых препаратов рассмотрены модели сокращения жизненного цикла отечественных научных разработок в формате использования преимуществ различных национальных инновационных экосистем и практик. Делается вывод о целесообразности воспроизведения жизненного цикла высокотехнологичного продукта в глобальном измерении ресурсов, рынков, инвестиций.</p></abstract><trans-abstract xml:lang="en"><p>The article demonstrates that alongside the process of trans-nationalizing the scientific driven and hightech production there is a trend arising in trans-nationalising scientific-technological sphere and global venture capital. There is evaluated the scale of the diffusion of Russian venture capital and its investment preferences. Using the examples of projects, related to the development of the new generation of antitumor drugs, there are analysed models for reducing the life cycle of domestic scientific developments in the format of using the benefits of various national innovation ecosystems and practices. A conclusion is made about the relevancy of reproduction of the life cycle of a high-tech product in the global scope of resources, markets and investments.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>высокотехнологичный продукт</kwd><kwd>жизненный цикл</kwd><kwd>сокращение</kwd><kwd>стадии коммерциализации</kwd><kwd>транснационализация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>high-tech product</kwd><kwd>life cycle</kwd><kwd>reduction</kwd><kwd>commercialisation stage</kwd><kwd>tran-snationalisation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вафина Н. Х. (2002) Транснационализация производства в свете теории самоорганизации экономических систем. М.: Издательство КГФИ. 316 с.</mixed-citation><mixed-citation xml:lang="en">Vafina N. Kh. (2002) Transnational productions in the light of the theory of  self-organisation of economic systems. Мoscow.: Izdatelstvo KFGI. 316 p.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Фрумкин К. (2016) Участвовать в революции. Российские олигархи ищут зарубежные стартапы / Компания, 18.04.2016. http://ko.ru/glavnoe/item/132235- uchastvovat-v-revolyutsi.</mixed-citation><mixed-citation xml:lang="en">Frumkin К. (2016) Participate in the revolution. Russian oligarchs are looking  for foreign startups / Company, 18.04.2016. http://ko.ru/glavnoe/item/132235- uchastvovat-v-revolyutsi.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кузнецова Т., Овчинникова О. (2007) Андрей Гудков: Мы слишком долго были на скамейке запасных / Новая газета, 26.11.2007. http://old.novayagazeta.ru/data/2007/kentavr07/00.html.</mixed-citation><mixed-citation xml:lang="en">Kuznetsova T., Ovchinnikova О. (2007) Andrey Gudkov: We have been sitting on the  substitutes bench for too long / Novaya gazeta, 26.11.2007. http://old.novayagazeta.ru/data/2007/kentavr07/00.html.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Молекулярный биолог Андрей Гудков: Рак и старость – братья-близнецы (2016) / Econet, 29.05.2016. http://econet.ru/articles/117789-molekulyarnyybiolog-andrey-gudkov- rak-i-starost-bratya-bliznetsy.</mixed-citation><mixed-citation xml:lang="en">Molecular biologist Andrey Gudkov: Cancer and an old age – brothers-twins (2016)  / Econet,29.05.2016. http://econet.ru/articles/117789-molekulyarnyy-biolog-andrey- gudkov-rak-i-starostbratya-bliznetsy.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">РОСНАНО и Cleveland BioLabs создают предприятие для разработки инновационных противораковых и антиинфекционных препаратов (2011) / Роснано, 26.09.2009. http://www.rusnano.com/about/press-centre/news/75694.</mixed-citation><mixed-citation xml:lang="en">ROSNANO and Cleveland BioLabs create an enterprise for developing innovative and  anti-cancer and anti-infection medication (2011) / Rosnano, 26.09.2009.  http://www.rusnano.com/about/presscentre/news/75694.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Product portfolio (2016) / Cleveland BioLabs. http://www.cbiolabs.com.</mixed-citation><mixed-citation xml:lang="en">Product portfolio (2016) / Cleveland BioLabs. http://www.cbiolabs.com.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cleveland BioLabs Inc – Form 8-K. Filed 11/05/14 for the Period Ending 11/05/14 (2014) / http://www.barchart.com/plmodules/?module=secFilings&amp;filingid=10282454&amp;type=CONVPDF&amp;popup=1&amp;override=1&amp;symbol=CB LI.</mixed-citation><mixed-citation xml:lang="en">Cleveland BioLabs Inc – Form 8-K. Filed 11/05/14 for the Period Ending 11/05/14  (2014) / http://www.barchart.com/plmodules/?module=secFilings&amp;filingid=10282454&amp;type=CONVPDF&amp;popup=1&amp;override=1&amp;symbol=CBLI.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Иванов А. (2014) Panacela Labs получит 146 млн рублей на исследования нового семейства медпрепаратов / ИТАР-ТАСС, 28.11.2014. http://tass.ru/nanotehnologii/1609074.</mixed-citation><mixed-citation xml:lang="en">Ivanov А. (2014) Panacela Labs will receive 146 million Rubles for research of  the new range of medication / TASS, 28.11.2014. http://tass.ru/nanotehnologii/1609074.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M–VM3) and Placebo in Patients With Prostate Cancer (2015) / ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT02654938.</mixed-citation><mixed-citation xml:lang="en">Safety and Tolerability Clinical Trial of Different Doses of the  Immunotherapeutic Drug Mobilan (M–VM3) and Placebo in Patients With Prostate Cancer (2015) / ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT02654938.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">ООО Инкурон (2016) / Инкурон. http://incuron.ru/ru/?s5_responsive_switch_incuronru=0.</mixed-citation><mixed-citation xml:lang="en">OOO Inkuron (2016) / Inkuron. http://incuron.ru/ru/? s5_responsive_switch_incuronru=0.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Тартис-Старение (2016) / Портал Сколково. https://sk.ru/net/1110133.</mixed-citation><mixed-citation xml:lang="en">Tartis-Starenie (2016) / Portal Skolkovo. https://sk.ru/net/1110133.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
